Safety and Performance of REGENERA Breast Implant in Women Affected by Malignant Breast Lesion Treated by Lumpectomy

Inclusion Criteria:

* Female adult subject aged 40-70 years.
* Subject diagnosed with malignant breast lesion:
* monolateral nodular infiltrative carcinoma,
* without microcalcification,
* single or multifocal,
* included in an area with a maximum diameter of 4 cm,
* non-metastatic (M0).
* Subject with clinically negative axilla.
* Subject considered eligible for conservative breast surgery - BCS (Breast-Conserving Surgery, lumpectomy or quadrantectomy), leaving a volume deficit compatible with a REGENERA implant (available in two dried sizes) volume of 70 ml or 100 ml.
* Confirmation of malignant lesion (pT1, pT2, pN0, pN1) with no discordance between biopsy and radiological imaging.
* Adequate hematopoietic functions.
* Good general health and mentally sound.
* Subject able and willing to give written informed consent form.

Exclusion Criteria:

* Subject with actual concomitant benign breast lesion (B2 and B3), unless present in the same mammary quadrant or in the contralateral breast.
* Subject with actual concomitant malignancies, lobular neoplasm, metastatic breast carcinoma, sarcoma, malignant phyllodes lesions, or Paget's disease.
* Axillary dissection planned as part of the breast lesion surgery.
* History of surgery, chemotherapy, neoadjuvant chemotherapy, or irradiation of the breast parenchyma object of the study.
* Skin retraction at the breast to be operated.
* Infection of the surgical site confirmed pre-operatively by clinical examination.
* Abnormal blood sugar and glycosylated hemoglobin.
* Hard smoker (more than 10 cigarettes a day).
* Acute or chronic severe renal insufficiency (creatinine values \>180 μmol/l).
* History of severe asthma or allergies (including allergy to anesthetics or contrast media).
* Autoimmune disease.
* Subjects who are known to be carriers of BCRA mutation.
* Inability to undergo MRI or allergy to contrast media.
* Systemic infections in an active phase.
* Immunocompromised patients (HIV).
* Pregnant or breastfeeding woman or woman who has nursed a child within 3 months prior to enrolment in the study.
* Subject who has participated in another interventional study within the past 3 months.
* Subject who received immunosuppressant therapy in the last 3 months.
* History of substance abuse (drug or alcohol).
* Non-collaborative patients (severe physical disabilities or psychiatric disorders, as per specialist opinion).